NZ245662A - Quinazoline derivatives, preparation and pharmaceutical compositions thereof - Google Patents
Quinazoline derivatives, preparation and pharmaceutical compositions thereofInfo
- Publication number
- NZ245662A NZ245662A NZ245662A NZ24566293A NZ245662A NZ 245662 A NZ245662 A NZ 245662A NZ 245662 A NZ245662 A NZ 245662A NZ 24566293 A NZ24566293 A NZ 24566293A NZ 245662 A NZ245662 A NZ 245662A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- alkoxy
- amino
- alkylamino
- quinazoline
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract description 5
- -1 hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims abstract description 338
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 267
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 150
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 34
- 239000001257 hydrogen Substances 0.000 claims abstract description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 26
- 125000005843 halogen group Chemical group 0.000 claims abstract description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 21
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 15
- 125000005530 alkylenedioxy group Chemical group 0.000 claims abstract description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims abstract description 7
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims abstract description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 5
- 125000000033 alkoxyamino group Chemical group 0.000 claims abstract description 4
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 102
- 150000003246 quinazolines Chemical class 0.000 claims description 85
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 80
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 22
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 18
- 125000004414 alkyl thio group Chemical group 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 16
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 15
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 14
- VKOGLNSKGDTRGH-UHFFFAOYSA-N 4-[(6-methoxyquinazolin-4-yl)amino]phenol Chemical compound C12=CC(OC)=CC=C2N=CN=C1NC1=CC=C(O)C=C1 VKOGLNSKGDTRGH-UHFFFAOYSA-N 0.000 claims description 13
- GBJXFMREUNFKRX-UHFFFAOYSA-N 4-n-(4-aminophenyl)quinazoline-4,6-diamine Chemical compound C1=CC(N)=CC=C1NC1=NC=NC2=CC=C(N)C=C12 GBJXFMREUNFKRX-UHFFFAOYSA-N 0.000 claims description 13
- JFDWMFYUKLPRSP-UHFFFAOYSA-N 6-methyl-n-phenylquinazolin-4-amine Chemical compound C12=CC(C)=CC=C2N=CN=C1NC1=CC=CC=C1 JFDWMFYUKLPRSP-UHFFFAOYSA-N 0.000 claims description 13
- 230000001093 anti-cancer Effects 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- CRZPVSMPJCPEPP-UHFFFAOYSA-N 4-([1,3]dioxolo[4,5-g]quinazolin-8-ylamino)phenol Chemical compound C1=CC(O)=CC=C1NC(C1=C2)=NC=NC1=CC1=C2OCO1 CRZPVSMPJCPEPP-UHFFFAOYSA-N 0.000 claims description 12
- MJKCGAHOCZLYDG-UHFFFAOYSA-N 6,7-dimethoxy-n-phenylquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC=C1 MJKCGAHOCZLYDG-UHFFFAOYSA-N 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- YPBYGBLLRMWZAF-UHFFFAOYSA-N 4-[(6,7,8-trimethoxyquinazolin-4-yl)amino]phenol Chemical compound N1=CN=C2C(OC)=C(OC)C(OC)=CC2=C1NC1=CC=C(O)C=C1 YPBYGBLLRMWZAF-UHFFFAOYSA-N 0.000 claims description 11
- 125000004423 acyloxy group Chemical group 0.000 claims description 10
- BYBQXGBBLHNCIR-UHFFFAOYSA-N 4-(4-chloroanilino)quinazolin-8-ol Chemical compound N1=CN=C2C(O)=CC=CC2=C1NC1=CC=C(Cl)C=C1 BYBQXGBBLHNCIR-UHFFFAOYSA-N 0.000 claims description 8
- ZFSSJGZFLIOOKN-UHFFFAOYSA-N 4-(4-methoxyanilino)quinazolin-8-ol Chemical compound C1=CC(OC)=CC=C1NC1=NC=NC2=C(O)C=CC=C12 ZFSSJGZFLIOOKN-UHFFFAOYSA-N 0.000 claims description 8
- URJYCHBAPFKHRE-UHFFFAOYSA-N 8-methoxy-n-(4-methoxyphenyl)quinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=NC2=C(OC)C=CC=C12 URJYCHBAPFKHRE-UHFFFAOYSA-N 0.000 claims description 7
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- MPIHIJBPYYKLEA-UHFFFAOYSA-N n-(4-chlorophenyl)-8-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C(OC)=CC=CC2=C1NC1=CC=C(Cl)C=C1 MPIHIJBPYYKLEA-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 230000029936 alkylation Effects 0.000 claims description 4
- 238000005804 alkylation reaction Methods 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- BCZUPYLJRTXVOY-UHFFFAOYSA-N 6,7-diethoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OCC)C(OCC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 BCZUPYLJRTXVOY-UHFFFAOYSA-N 0.000 claims description 3
- YMQNMNWEDFTMTJ-UHFFFAOYSA-N 6-n,6-n-dimethyl-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(N(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 YMQNMNWEDFTMTJ-UHFFFAOYSA-N 0.000 claims description 3
- BWENYVDMLAZGTP-UHFFFAOYSA-N 7-methoxy-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C=12C=C(N)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 BWENYVDMLAZGTP-UHFFFAOYSA-N 0.000 claims description 3
- WLGDTJBSQGRVRX-UHFFFAOYSA-N [4-(3-methylanilino)quinazolin-6-yl]urea Chemical compound CC1=CC=CC(NC=2C3=CC(NC(N)=O)=CC=C3N=CN=2)=C1 WLGDTJBSQGRVRX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims description 3
- BIGXXKQBMRKUJG-UHFFFAOYSA-N n-(3-methylphenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC=4OCCOC=4C=C3N=CN=2)=C1 BIGXXKQBMRKUJG-UHFFFAOYSA-N 0.000 claims description 3
- VQIWZLBIZSXBLT-UHFFFAOYSA-N n-[4-(3-methylanilino)quinazolin-6-yl]benzamide Chemical compound CC1=CC=CC(NC=2C3=CC(NC(=O)C=4C=CC=CC=4)=CC=C3N=CN=2)=C1 VQIWZLBIZSXBLT-UHFFFAOYSA-N 0.000 claims description 3
- QYXLGBIMSTYMHA-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-nitrophenyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC([N+]([O-])=O)=C1 QYXLGBIMSTYMHA-UHFFFAOYSA-N 0.000 claims description 2
- ULUILBSHRZPHGK-UHFFFAOYSA-N 6-(2-methoxyethoxymethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(COCCOC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 ULUILBSHRZPHGK-UHFFFAOYSA-N 0.000 claims description 2
- ZJCCYDYNZMGIHC-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(OC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 ZJCCYDYNZMGIHC-UHFFFAOYSA-N 0.000 claims description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 2
- NZHRGFLNIISRAV-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1 NZHRGFLNIISRAV-UHFFFAOYSA-N 0.000 claims description 2
- JDEKFVYZUIPHET-UHFFFAOYSA-N n-(3-chlorophenyl)-6-methoxyquinazolin-4-amine Chemical compound C12=CC(OC)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 JDEKFVYZUIPHET-UHFFFAOYSA-N 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- ACCVTKJXKFSAAH-UHFFFAOYSA-N 5-methoxyquinazoline Chemical compound C1=NC=C2C(OC)=CC=CC2=N1 ACCVTKJXKFSAAH-UHFFFAOYSA-N 0.000 claims 1
- MCBABIOGLXZCHP-UHFFFAOYSA-N 6,7-dimethoxy-n-phenylquinazolin-2-amine Chemical compound N1=C2C=C(OC)C(OC)=CC2=CN=C1NC1=CC=CC=C1 MCBABIOGLXZCHP-UHFFFAOYSA-N 0.000 claims 1
- UWSJFQYJMQTBQA-UHFFFAOYSA-N 6-methyl-N-phenylquinazolin-2-amine Chemical compound N1=CC2=CC(C)=CC=C2N=C1NC1=CC=CC=C1 UWSJFQYJMQTBQA-UHFFFAOYSA-N 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract description 16
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 13
- 201000011510 cancer Diseases 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 description 299
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 201
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- 238000000921 elemental analysis Methods 0.000 description 85
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- 239000000243 solution Substances 0.000 description 57
- 238000004440 column chromatography Methods 0.000 description 56
- 239000003480 eluent Substances 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 49
- 239000007858 starting material Substances 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 238000010992 reflux Methods 0.000 description 36
- 239000000047 product Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
- 239000002244 precipitate Substances 0.000 description 26
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 20
- 239000012258 stirred mixture Substances 0.000 description 20
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- NFBCSWGEYDCCDW-UHFFFAOYSA-N 4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound CC1=CC=CC(NC=2C3=CC(N)=CC=C3N=CN=2)=C1 NFBCSWGEYDCCDW-UHFFFAOYSA-N 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- CMYBAHRLNADCKS-UHFFFAOYSA-N 6-(bromomethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CBr)=CC=C3N=CN=2)=C1 CMYBAHRLNADCKS-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 8
- KPHNOFBKQHPSGB-UHFFFAOYSA-N 6-methoxy-4-(3-methylanilino)quinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1NC1=CC=CC(C)=C1 KPHNOFBKQHPSGB-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 102400001368 Epidermal growth factor Human genes 0.000 description 7
- 101800003838 Epidermal growth factor Proteins 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 229940116977 epidermal growth factor Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000003701 inert diluent Substances 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- MBEQLZLCWSXTPD-UHFFFAOYSA-N 4-(3-methylanilino)quinazoline-6,7-diol Chemical compound CC1=CC=CC(NC=2C3=CC(O)=C(O)C=C3N=CN=2)=C1 MBEQLZLCWSXTPD-UHFFFAOYSA-N 0.000 description 5
- FUWFVMHHNPEPHD-UHFFFAOYSA-N 6-(bromomethyl)-4-chloroquinazoline Chemical compound C1=C(CBr)C=C2C(Cl)=NC=NC2=C1 FUWFVMHHNPEPHD-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- ZFXHOCBCURBSDT-UHFFFAOYSA-N 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyethanol Chemical compound N1=CN=C2C=C(OCCO)C(OC)=CC2=C1NC1=CC=CC(C)=C1 ZFXHOCBCURBSDT-UHFFFAOYSA-N 0.000 description 4
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 4
- LZOSFEDULGODDH-UHFFFAOYSA-N 4-chloro-6-nitroquinazoline Chemical compound N1=CN=C(Cl)C2=CC([N+](=O)[O-])=CC=C21 LZOSFEDULGODDH-UHFFFAOYSA-N 0.000 description 4
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical class C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 4
- AWAYNEMCHILZCF-UHFFFAOYSA-N 4-n-(3-chlorophenyl)quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 AWAYNEMCHILZCF-UHFFFAOYSA-N 0.000 description 4
- AHGSPAKNJWCSRF-UHFFFAOYSA-N 4-n-(3-methylphenyl)quinazoline-4,7-diamine Chemical compound CC1=CC=CC(NC=2C3=CC=C(N)C=C3N=CN=2)=C1 AHGSPAKNJWCSRF-UHFFFAOYSA-N 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- RSVNNWQHWIOIOC-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 RSVNNWQHWIOIOC-UHFFFAOYSA-N 0.000 description 4
- BUYIXGTWVMBDLP-UHFFFAOYSA-N 7-chloro-n-(3-methylphenyl)-6-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(=C(Cl)C=C3N=CN=2)[N+]([O-])=O)=C1 BUYIXGTWVMBDLP-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- UMKSAURFQFUULT-UHFFFAOYSA-N 2-Amino-5-methoxybenzoic acid Chemical compound COC1=CC=C(N)C(C(O)=O)=C1 UMKSAURFQFUULT-UHFFFAOYSA-N 0.000 description 3
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- ZKUYSJHXBFFGPU-UHFFFAOYSA-N 2516-95-2 Chemical compound OC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O ZKUYSJHXBFFGPU-UHFFFAOYSA-N 0.000 description 3
- YIEFGGZKSXIYFW-UHFFFAOYSA-N 4-(3-methylanilino)quinazoline-7-carboxylic acid Chemical compound CC1=CC=CC(NC=2C3=CC=C(C=C3N=CN=2)C(O)=O)=C1 YIEFGGZKSXIYFW-UHFFFAOYSA-N 0.000 description 3
- ATRZVHJSCCURLJ-UHFFFAOYSA-N 4-(4-chloroquinazolin-6-yl)morpholine Chemical compound C1=C2C(Cl)=NC=NC2=CC=C1N1CCOCC1 ATRZVHJSCCURLJ-UHFFFAOYSA-N 0.000 description 3
- XNILKVADCMYCQT-UHFFFAOYSA-N 4-chloro-6-methylquinazoline Chemical compound N1=CN=C(Cl)C2=CC(C)=CC=C21 XNILKVADCMYCQT-UHFFFAOYSA-N 0.000 description 3
- ASLFKOTWRWCLSK-UHFFFAOYSA-N 4-chloro-6-piperidin-1-ylquinazoline Chemical compound C1=C2C(Cl)=NC=NC2=CC=C1N1CCCCC1 ASLFKOTWRWCLSK-UHFFFAOYSA-N 0.000 description 3
- HDXUENATWBWIRX-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-methylphenyl)-5-nitroquinazolin-4-amine Chemical compound C=12C([N+]([O-])=O)=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 HDXUENATWBWIRX-UHFFFAOYSA-N 0.000 description 3
- JHWXBNQNSFQNPY-UHFFFAOYSA-N 7-(2-bromoethoxy)-6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCBr)C(OC)=CC2=C1NC1=CC=CC(C)=C1 JHWXBNQNSFQNPY-UHFFFAOYSA-N 0.000 description 3
- PMLONMIODRHERC-UHFFFAOYSA-N 7-chloro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C=2C1=CC(Cl)=CC=2 PMLONMIODRHERC-UHFFFAOYSA-N 0.000 description 3
- WZLMWRBGVYVLDZ-UHFFFAOYSA-N 7-methoxy-n-(3-methylphenyl)-6-nitroquinazolin-4-amine Chemical compound C=12C=C([N+]([O-])=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 WZLMWRBGVYVLDZ-UHFFFAOYSA-N 0.000 description 3
- HQQMBKAUTNDSQY-UHFFFAOYSA-N 7-n-[3-(dimethylamino)propyl]-4-n-(3-methylphenyl)-6-nitroquinazoline-4,7-diamine Chemical compound C=12C=C([N+]([O-])=O)C(NCCCN(C)C)=CC2=NC=NC=1NC1=CC=CC(C)=C1 HQQMBKAUTNDSQY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- DNZMCCLHPQTXJQ-UHFFFAOYSA-N methyl 4-(3-methylanilino)quinazoline-7-carboxylate Chemical compound N=1C=NC2=CC(C(=O)OC)=CC=C2C=1NC1=CC=CC(C)=C1 DNZMCCLHPQTXJQ-UHFFFAOYSA-N 0.000 description 3
- CSOBGYJJXIKZGA-UHFFFAOYSA-N n-(3-methylphenyl)-6-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)[N+]([O-])=O)=C1 CSOBGYJJXIKZGA-UHFFFAOYSA-N 0.000 description 3
- HGIWILAPVIDGKH-UHFFFAOYSA-N n-(3-methylphenyl)-7-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC=C(C=C3N=CN=2)[N+]([O-])=O)=C1 HGIWILAPVIDGKH-UHFFFAOYSA-N 0.000 description 3
- ZNHMGZYTJLEROX-UHFFFAOYSA-N n-[4-(3-methylanilino)quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 ZNHMGZYTJLEROX-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- LSBGXLOBLBWVEN-UHFFFAOYSA-N (4-chloroquinazolin-6-yl) acetate Chemical compound N1=CN=C(Cl)C2=CC(OC(=O)C)=CC=C21 LSBGXLOBLBWVEN-UHFFFAOYSA-N 0.000 description 2
- HJVAVGOPTDJYOJ-UHFFFAOYSA-N 2-amino-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(N)=C(C(O)=O)C=C1OC HJVAVGOPTDJYOJ-UHFFFAOYSA-N 0.000 description 2
- JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 2
- RUYCUDHAVDCXIX-UHFFFAOYSA-N 2-chloro-n-[4-(3-methylanilino)quinazolin-6-yl]acetamide Chemical compound CC1=CC=CC(NC=2C3=CC(NC(=O)CCl)=CC=C3N=CN=2)=C1 RUYCUDHAVDCXIX-UHFFFAOYSA-N 0.000 description 2
- KUOMDAPBHJIEKP-UHFFFAOYSA-N 2-methoxy-n-[4-(3-methylanilino)quinazolin-7-yl]acetamide Chemical compound N=1C=NC2=CC(NC(=O)COC)=CC=C2C=1NC1=CC=CC(C)=C1 KUOMDAPBHJIEKP-UHFFFAOYSA-N 0.000 description 2
- MJLHSJRIMKQIFP-UHFFFAOYSA-N 3-n-(6,7-dimethoxyquinazolin-4-yl)benzene-1,3-diamine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(N)=C1 MJLHSJRIMKQIFP-UHFFFAOYSA-N 0.000 description 2
- ZQIWRIWTTKXCIO-UHFFFAOYSA-N 4-(3-methylanilino)quinazolin-7-ol Chemical compound CC1=CC=CC(NC=2C3=CC=C(O)C=C3N=CN=2)=C1 ZQIWRIWTTKXCIO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CCCGYXZEVXWXAU-UHFFFAOYSA-N 4-chloro-7-nitroquinazoline Chemical compound ClC1=NC=NC2=CC([N+](=O)[O-])=CC=C21 CCCGYXZEVXWXAU-UHFFFAOYSA-N 0.000 description 2
- SBGUQHNSYZGPLX-UHFFFAOYSA-N 4-n-(3-methylphenyl)-7-morpholin-4-ylquinazoline-4,6-diamine Chemical compound CC1=CC=CC(NC=2C3=CC(N)=C(N4CCOCC4)C=C3N=CN=2)=C1 SBGUQHNSYZGPLX-UHFFFAOYSA-N 0.000 description 2
- DLVMGJPGJHCIJW-UHFFFAOYSA-N 4-n-[3-(trifluoromethyl)phenyl]quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NC1=CC=CC(C(F)(F)F)=C1 DLVMGJPGJHCIJW-UHFFFAOYSA-N 0.000 description 2
- TWDBGKCEJPCGEK-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(OCCBr)=CC=C3N=CN=2)=C1 TWDBGKCEJPCGEK-UHFFFAOYSA-N 0.000 description 2
- QJRNXXLTDWMENM-UHFFFAOYSA-N 6-hydroxy-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(O)=CC=C21 QJRNXXLTDWMENM-UHFFFAOYSA-N 0.000 description 2
- VVNQBWHRGUXZNH-UHFFFAOYSA-N 6-methoxy-7-(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 VVNQBWHRGUXZNH-UHFFFAOYSA-N 0.000 description 2
- JUCDXPIFJIVICL-UHFFFAOYSA-N 6-methyl-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(C)=CC=C21 JUCDXPIFJIVICL-UHFFFAOYSA-N 0.000 description 2
- AHEHMDXRXAAMGF-UHFFFAOYSA-N 6-methyl-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(C)=CC=C3N=CN=2)=C1 AHEHMDXRXAAMGF-UHFFFAOYSA-N 0.000 description 2
- KHYGXPXJZPATPD-UHFFFAOYSA-N 6-n-(2-methoxyethyl)-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(NCCOC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 KHYGXPXJZPATPD-UHFFFAOYSA-N 0.000 description 2
- MOBNCKURXDGQCB-UHFFFAOYSA-N 6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC([N+](=O)[O-])=CC=C21 MOBNCKURXDGQCB-UHFFFAOYSA-N 0.000 description 2
- FKOOZPWZRRDRTK-UHFFFAOYSA-N 6-nitro-n-[3-(trifluoromethyl)phenyl]quinazolin-4-amine Chemical compound C12=CC([N+](=O)[O-])=CC=C2N=CN=C1NC1=CC=CC(C(F)(F)F)=C1 FKOOZPWZRRDRTK-UHFFFAOYSA-N 0.000 description 2
- URDYTQYZXZKBQT-UHFFFAOYSA-N 7-chloro-6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C=C(Cl)C([N+](=O)[O-])=C2 URDYTQYZXZKBQT-UHFFFAOYSA-N 0.000 description 2
- KCLLIYLLKJSXGQ-UHFFFAOYSA-N 7-methoxy-4-(3-methylanilino)quinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 KCLLIYLLKJSXGQ-UHFFFAOYSA-N 0.000 description 2
- GHEITLVPLGZZQI-UHFFFAOYSA-N 7-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N=1C=NC2=CC(OC)=CC=C2C=1NC1=CC=CC(C)=C1 GHEITLVPLGZZQI-UHFFFAOYSA-N 0.000 description 2
- NBVNEDHQRFJKCG-UHFFFAOYSA-N 7-n-methyl-4-n-(3-methylphenyl)-6-nitroquinazoline-4,7-diamine Chemical compound C=12C=C([N+]([O-])=O)C(NC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 NBVNEDHQRFJKCG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- PWRPUAKXMQAFCJ-UHFFFAOYSA-N Perlapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2CC2=CC=CC=C12 PWRPUAKXMQAFCJ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001348 alkyl chlorides Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- WGDFCNRIGUMPIC-UHFFFAOYSA-N ethyl 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyacetate Chemical compound C=12C=C(OC)C(OCC(=O)OCC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 WGDFCNRIGUMPIC-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- BYHDRGRVVXBJIP-UHFFFAOYSA-N methyl 4-chloroquinazoline-7-carboxylate Chemical compound ClC1=NC=NC2=CC(C(=O)OC)=CC=C21 BYHDRGRVVXBJIP-UHFFFAOYSA-N 0.000 description 2
- USAMIYATKINXLP-UHFFFAOYSA-N n-(3-chlorophenyl)-6-nitroquinazolin-4-amine Chemical compound C12=CC([N+](=O)[O-])=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 USAMIYATKINXLP-UHFFFAOYSA-N 0.000 description 2
- IVUMMNZRJFAFQP-UHFFFAOYSA-N n-(3-methylphenyl)-7-methylsulfanyl-6-nitroquinazolin-4-amine Chemical compound C=12C=C([N+]([O-])=O)C(SC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 IVUMMNZRJFAFQP-UHFFFAOYSA-N 0.000 description 2
- QNNZNPUJXPQPJI-UHFFFAOYSA-N n-(3-methylphenyl)-7-morpholin-4-yl-6-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(=C(N4CCOCC4)C=C3N=CN=2)[N+]([O-])=O)=C1 QNNZNPUJXPQPJI-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 2
- QHSILJZBWLFQGR-UHFFFAOYSA-N (4-oxo-1h-quinazolin-6-yl) acetate Chemical compound N1=CNC(=O)C2=CC(OC(=O)C)=CC=C21 QHSILJZBWLFQGR-UHFFFAOYSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- XSHQBIXMLULFEV-UHFFFAOYSA-N 1-NA-PP1 Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)N=C1C1=CC=CC2=CC=CC=C12 XSHQBIXMLULFEV-UHFFFAOYSA-N 0.000 description 1
- ZQRROVFSALJMMI-UHFFFAOYSA-N 1-[4-(3-methylanilino)quinazolin-6-yl]-3-phenylurea Chemical compound CC1=CC=CC(NC=2C3=CC(NC(=O)NC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 ZQRROVFSALJMMI-UHFFFAOYSA-N 0.000 description 1
- UDJDCUHZIBKBJL-UHFFFAOYSA-N 1-[4-(3-methylanilino)quinazolin-6-yl]pyrrolidin-2-one Chemical compound CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)N2C(CCC2)=O)=C1 UDJDCUHZIBKBJL-UHFFFAOYSA-N 0.000 description 1
- UVWNVPIDUAYZDR-UHFFFAOYSA-N 1-[4-(3-methylanilino)quinazolin-6-yl]pyrrolidine-2,5-dione Chemical compound CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)N2C(CCC2=O)=O)=C1 UVWNVPIDUAYZDR-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- LDKSCZJUIURGMW-UHFFFAOYSA-N 1-isothiocyanato-3-methylsulfanylpropane Chemical group CSCCCN=C=S LDKSCZJUIURGMW-UHFFFAOYSA-N 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- HYNQTSZBTIOFKH-UHFFFAOYSA-N 2-Amino-5-hydroxybenzoic acid Chemical compound NC1=CC=C(O)C=C1C(O)=O HYNQTSZBTIOFKH-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JXSIKEXWVFQUAR-UHFFFAOYSA-N 2-[4-(3-methylanilino)quinazolin-6-yl]acetonitrile Chemical compound CC1=CC=CC(NC=2C3=CC(CC#N)=CC=C3N=CN=2)=C1 JXSIKEXWVFQUAR-UHFFFAOYSA-N 0.000 description 1
- WWTDYEGPACEFBZ-UHFFFAOYSA-N 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyacetamide Chemical compound N1=CN=C2C=C(OCC(N)=O)C(OC)=CC2=C1NC1=CC=CC(C)=C1 WWTDYEGPACEFBZ-UHFFFAOYSA-N 0.000 description 1
- JJRIZRKUNDUATE-UHFFFAOYSA-N 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyacetic acid Chemical compound N1=CN=C2C=C(OCC(O)=O)C(OC)=CC2=C1NC1=CC=CC(C)=C1 JJRIZRKUNDUATE-UHFFFAOYSA-N 0.000 description 1
- HVOXXLLDKLJFND-UHFFFAOYSA-N 2-[7-(2-hydroxyethoxy)-4-(3-methylanilino)quinazolin-6-yl]oxyethanol Chemical compound CC1=CC=CC(NC=2C3=CC(OCCO)=C(OCCO)C=C3N=CN=2)=C1 HVOXXLLDKLJFND-UHFFFAOYSA-N 0.000 description 1
- PEVPLGLOMADHAE-UHFFFAOYSA-N 2-[[4-(3-methylanilino)quinazolin-6-yl]methylsulfanyl]ethanol Chemical compound CC1=CC=CC(NC=2C3=CC(CSCCO)=CC=C3N=CN=2)=C1 PEVPLGLOMADHAE-UHFFFAOYSA-N 0.000 description 1
- KBCHMLUJHCFUST-UHFFFAOYSA-N 2-[[4-(3-methylanilino)quinazolin-7-yl]amino]ethanol Chemical compound CC1=CC=CC(NC=2C3=CC=C(NCCO)C=C3N=CN=2)=C1 KBCHMLUJHCFUST-UHFFFAOYSA-N 0.000 description 1
- REBBDMHTSKPGCO-UHFFFAOYSA-N 2-amino-4,5-dimethylbenzoic acid Chemical compound CC1=CC(N)=C(C(O)=O)C=C1C REBBDMHTSKPGCO-UHFFFAOYSA-N 0.000 description 1
- HHNWXQCVWVVVQZ-UHFFFAOYSA-N 2-amino-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(N)=C1 HHNWXQCVWVVVQZ-UHFFFAOYSA-N 0.000 description 1
- UXNGDCBPIGOZFO-UHFFFAOYSA-N 2-amino-5-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(OC(F)(F)F)C=C1C(O)=O UXNGDCBPIGOZFO-UHFFFAOYSA-N 0.000 description 1
- HFHMPAKMODSNJN-UHFFFAOYSA-N 2-amino-5-morpholin-4-ylbenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC=C1N1CCOCC1 HFHMPAKMODSNJN-UHFFFAOYSA-N 0.000 description 1
- DNABDRZWPKYYTH-UHFFFAOYSA-N 2-amino-5-piperidin-1-ylbenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC=C1N1CCCCC1 DNABDRZWPKYYTH-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- GPNNOCMCNFXRAO-UHFFFAOYSA-N 2-aminoterephthalic acid Chemical compound NC1=CC(C(O)=O)=CC=C1C(O)=O GPNNOCMCNFXRAO-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- FMTHDYACPOHXSC-UHFFFAOYSA-N 2-n-(6,7-dimethoxyquinazolin-4-yl)benzene-1,2-diamine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC=C1N FMTHDYACPOHXSC-UHFFFAOYSA-N 0.000 description 1
- RPNHCXPJSUGRAB-UHFFFAOYSA-N 2-nitro-5-(piperidin-1-yl)benzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(N2CCCCC2)=C1 RPNHCXPJSUGRAB-UHFFFAOYSA-N 0.000 description 1
- AWYDPLFHUNXJRH-UHFFFAOYSA-N 3,3,3-trifluoro-2-methyl-n-phenylpropanamide Chemical compound FC(F)(F)C(C)C(=O)NC1=CC=CC=C1 AWYDPLFHUNXJRH-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 description 1
- BTBVSLMBNRBDIR-UHFFFAOYSA-N 4-(3-chloroanilino)quinazoline-6,7-diol Chemical compound C=12C=C(O)C(O)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 BTBVSLMBNRBDIR-UHFFFAOYSA-N 0.000 description 1
- ZLNPUJYIVLCGAY-UHFFFAOYSA-N 4-(3-methylanilino)quinazolin-6-ol Chemical compound CC1=CC=CC(NC=2C3=CC(O)=CC=C3N=CN=2)=C1 ZLNPUJYIVLCGAY-UHFFFAOYSA-N 0.000 description 1
- RWLYIYZYVWCDJW-UHFFFAOYSA-N 4-(quinazolin-4-ylamino)phenol Chemical class C1=CC(O)=CC=C1NC1=NC=NC2=CC=CC=C12 RWLYIYZYVWCDJW-UHFFFAOYSA-N 0.000 description 1
- BNDYIYYKEIXHNK-UHFFFAOYSA-N 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(O)=C1 BNDYIYYKEIXHNK-UHFFFAOYSA-N 0.000 description 1
- WIKQNBCDJYNKED-UHFFFAOYSA-N 4-chloro-6,7-dimethylquinazoline Chemical compound C1=NC(Cl)=C2C=C(C)C(C)=CC2=N1 WIKQNBCDJYNKED-UHFFFAOYSA-N 0.000 description 1
- QNLKPXGXCBGDDC-UHFFFAOYSA-N 4-chloro-6-(dibromomethyl)quinazoline Chemical compound C1=C(C(Br)Br)C=C2C(Cl)=NC=NC2=C1 QNLKPXGXCBGDDC-UHFFFAOYSA-N 0.000 description 1
- ZGIDAXLBBURWOL-UHFFFAOYSA-N 4-chloro-6-(trifluoromethoxy)quinazoline Chemical compound N1=CN=C(Cl)C2=CC(OC(F)(F)F)=CC=C21 ZGIDAXLBBURWOL-UHFFFAOYSA-N 0.000 description 1
- MREJJMASIQVOTH-UHFFFAOYSA-N 4-chloro-6-methoxyquinazoline Chemical compound N1=CN=C(Cl)C2=CC(OC)=CC=C21 MREJJMASIQVOTH-UHFFFAOYSA-N 0.000 description 1
- GUQZHZBMDPEBQG-UHFFFAOYSA-N 4-chloro-7-methoxyquinazoline Chemical compound ClC1=NC=NC2=CC(OC)=CC=C21 GUQZHZBMDPEBQG-UHFFFAOYSA-N 0.000 description 1
- SQSSULVYIBYQSG-UHFFFAOYSA-N 4-n-(3-methylphenyl)-7-methylsulfanylquinazoline-4,6-diamine Chemical compound C=12C=C(N)C(SC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 SQSSULVYIBYQSG-UHFFFAOYSA-N 0.000 description 1
- WIEWJZVAKXFUTG-UHFFFAOYSA-N 4-n-(6,7-dimethoxyquinazolin-4-yl)benzene-1,4-diamine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(N)C=C1 WIEWJZVAKXFUTG-UHFFFAOYSA-N 0.000 description 1
- UEALKTCRMBVTFN-UHFFFAOYSA-N 4-nitroanthranilic acid Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(O)=O UEALKTCRMBVTFN-UHFFFAOYSA-N 0.000 description 1
- ICASWNVSUDFGRH-UHFFFAOYSA-N 4-oxo-1h-quinazoline-7-carboxylic acid Chemical compound N1C=NC(=O)C=2C1=CC(C(=O)O)=CC=2 ICASWNVSUDFGRH-UHFFFAOYSA-N 0.000 description 1
- AGQATLDTZCPZJT-UHFFFAOYSA-N 4-quinazolin-6-ylmorpholine Chemical compound C1COCCN1C1=CC=C(N=CN=C2)C2=C1 AGQATLDTZCPZJT-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- YLZSNFZNVCUXMM-UHFFFAOYSA-N 5-morpholin-4-yl-2-nitrobenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(N2CCOCC2)=C1 YLZSNFZNVCUXMM-UHFFFAOYSA-N 0.000 description 1
- RUCHWTKMOWXHLU-UHFFFAOYSA-N 5-nitroanthranilic acid Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(O)=O RUCHWTKMOWXHLU-UHFFFAOYSA-N 0.000 description 1
- RHISQWTXRCBOBJ-UHFFFAOYSA-N 6,7,8-trimethoxyquinazoline Chemical class N1=CN=C2C(OC)=C(OC)C(OC)=CC2=C1 RHISQWTXRCBOBJ-UHFFFAOYSA-N 0.000 description 1
- GQZJIWRQFUXHGZ-UHFFFAOYSA-N 6,7-bis(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 GQZJIWRQFUXHGZ-UHFFFAOYSA-N 0.000 description 1
- DMSRMHGCZUXCMJ-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(OC)C(OC)=CC2=N1 DMSRMHGCZUXCMJ-UHFFFAOYSA-N 0.000 description 1
- NJPNKDPGKPSJPR-UHFFFAOYSA-N 6,7-dimethoxy-4-n-(3-methylphenyl)quinazoline-4,5-diamine Chemical compound C=12C(N)=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 NJPNKDPGKPSJPR-UHFFFAOYSA-N 0.000 description 1
- JBTUFBGGRVLCFF-UHFFFAOYSA-N 6,7-dimethoxy-5-nitro-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=C1C=C(OC)C(OC)=C2[N+]([O-])=O JBTUFBGGRVLCFF-UHFFFAOYSA-N 0.000 description 1
- PBHYWXWANPMYSG-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 PBHYWXWANPMYSG-UHFFFAOYSA-N 0.000 description 1
- KEQCEKUDWPXRRQ-UHFFFAOYSA-N 6,7-dimethoxy-n-[3-(trifluoromethyl)phenyl]quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C(F)(F)F)=C1 KEQCEKUDWPXRRQ-UHFFFAOYSA-N 0.000 description 1
- POXXGTPTPULVDC-UHFFFAOYSA-N 6-(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(OCCOC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 POXXGTPTPULVDC-UHFFFAOYSA-N 0.000 description 1
- VQHITFFJBFOMBG-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-11h-benzo[b][1,4]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=CC=CC=C12 VQHITFFJBFOMBG-UHFFFAOYSA-N 0.000 description 1
- YIWFXXWSEKDDJR-UHFFFAOYSA-N 6-(anilinomethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CNC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 YIWFXXWSEKDDJR-UHFFFAOYSA-N 0.000 description 1
- LVIPTUOEUDTIFD-UHFFFAOYSA-N 6-(anilinomethyl)-n-(3-methylphenyl)quinazolin-4-amine;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC(NC=2C3=CC(CNC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 LVIPTUOEUDTIFD-UHFFFAOYSA-N 0.000 description 1
- OCAWACKWBYEOSN-UHFFFAOYSA-N 6-(methoxymethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(COC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 OCAWACKWBYEOSN-UHFFFAOYSA-N 0.000 description 1
- MBWSFACVGYJPPE-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(CN(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MBWSFACVGYJPPE-UHFFFAOYSA-N 0.000 description 1
- TVHKDIOQVKDWQQ-UHFFFAOYSA-N 6-[2-(dimethylamino)ethoxy]-n-(3-methylphenyl)quinazolin-4-amine;hydrobromide Chemical compound Br.C12=CC(OCCN(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 TVHKDIOQVKDWQQ-UHFFFAOYSA-N 0.000 description 1
- OJTOAMSTANUUMJ-UHFFFAOYSA-N 6-amino-1,3-benzodioxole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N)=CC2=C1OCO2 OJTOAMSTANUUMJ-UHFFFAOYSA-N 0.000 description 1
- WWSGQFXMLMGYJK-UHFFFAOYSA-N 6-chloro-n-phenylquinazolin-4-amine Chemical compound C12=CC(Cl)=CC=C2N=CN=C1NC1=CC=CC=C1 WWSGQFXMLMGYJK-UHFFFAOYSA-N 0.000 description 1
- KKAHSVDGWDURSJ-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)-7-(2-morpholin-4-ylethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN3CCOCC3)C(OC)=CC2=C1NC1=CC=CC(C)=C1 KKAHSVDGWDURSJ-UHFFFAOYSA-N 0.000 description 1
- KAAXGUNWEKNMHS-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)-7-phenylmethoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=CC(C)=C1 KAAXGUNWEKNMHS-UHFFFAOYSA-N 0.000 description 1
- PWWZQDDEXXYYHZ-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)-7-propan-2-yloxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC(C)C)C(OC)=CC2=C1NC1=CC=CC(C)=C1 PWWZQDDEXXYYHZ-UHFFFAOYSA-N 0.000 description 1
- LNUACJNTNFFFCF-UHFFFAOYSA-N 6-morpholin-4-yl-1h-quinazolin-4-one Chemical compound C1=C2C(=O)NC=NC2=CC=C1N1CCOCC1 LNUACJNTNFFFCF-UHFFFAOYSA-N 0.000 description 1
- XDJSMRNTCLSXNA-UHFFFAOYSA-N 6-n-benzyl-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound CC1=CC=CC(NC=2C3=CC(NCC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 XDJSMRNTCLSXNA-UHFFFAOYSA-N 0.000 description 1
- IWBVCRRXSCJLQC-UHFFFAOYSA-N 6-n-methyl-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(NC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 IWBVCRRXSCJLQC-UHFFFAOYSA-N 0.000 description 1
- JCBYXNSOLUVGTF-UHFFFAOYSA-N 6-piperazin-1-yl-11h-benzo[b][1,4]benzodiazepine Chemical compound C1CNCCN1C1=NC2=CC=CC=C2NC2=CC=CC=C12 JCBYXNSOLUVGTF-UHFFFAOYSA-N 0.000 description 1
- SVFHMJGZJXLEIF-UHFFFAOYSA-N 6-piperidin-1-yl-1h-quinazolin-4-one Chemical compound C1=C2C(=O)NC=NC2=CC=C1N1CCCCC1 SVFHMJGZJXLEIF-UHFFFAOYSA-N 0.000 description 1
- ITFLBRGWNXCRFJ-UHFFFAOYSA-N 6-piperidin-1-ylquinazoline Chemical compound C1CCCCN1C1=CC=C(N=CN=C2)C2=C1 ITFLBRGWNXCRFJ-UHFFFAOYSA-N 0.000 description 1
- NKLHAODPKDGWMZ-UHFFFAOYSA-N 7-(2-anilinoethoxy)-6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCNC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=CC(C)=C1 NKLHAODPKDGWMZ-UHFFFAOYSA-N 0.000 description 1
- CZUUUCCKUDTMKH-UHFFFAOYSA-N 7-[2-(dimethylamino)ethoxy]-6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN(C)C)C(OC)=CC2=C1NC1=CC=CC(C)=C1 CZUUUCCKUDTMKH-UHFFFAOYSA-N 0.000 description 1
- HLIHEQQVUVVQDD-UHFFFAOYSA-N 7-n-[3-(dimethylamino)propyl]-4-n-(3-methylphenyl)quinazoline-4,6,7-triamine Chemical compound C=12C=C(N)C(NCCCN(C)C)=CC2=NC=NC=1NC1=CC=CC(C)=C1 HLIHEQQVUVVQDD-UHFFFAOYSA-N 0.000 description 1
- DYEVXLNQIXWWDH-UHFFFAOYSA-N 7-n-methyl-4-n-(3-methylphenyl)quinazoline-4,6,7-triamine Chemical compound C=12C=C(N)C(NC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 DYEVXLNQIXWWDH-UHFFFAOYSA-N 0.000 description 1
- RZCJSVRGPHXBSM-UHFFFAOYSA-N 8-chloro-[1,3]dioxolo[4,5-g]quinazoline Chemical compound C1=C2C(Cl)=NC=NC2=CC2=C1OCO2 RZCJSVRGPHXBSM-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- AGIOYQIKFISKCK-UHFFFAOYSA-N [4-(3-methylanilino)quinazolin-7-yl]methanol Chemical compound CC1=CC=CC(NC=2C3=CC=C(CO)C=C3N=CN=2)=C1 AGIOYQIKFISKCK-UHFFFAOYSA-N 0.000 description 1
- OECAAUNBQHKSFL-UHFFFAOYSA-N [6-methoxy-4-(3-methylanilino)quinazolin-7-yl] 2-methoxyacetate Chemical compound C=12C=C(OC)C(OC(=O)COC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 OECAAUNBQHKSFL-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010060350 arginyl-arginyl-leucyl-isoleucyl-glutamyl-aspartyl-alanyl-glutamyl-tyrosyl-alanyl-alanyl-arginyl-glycine Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- IRXBNHGNHKNOJI-UHFFFAOYSA-N butanedioyl dichloride Chemical compound ClC(=O)CCC(Cl)=O IRXBNHGNHKNOJI-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- MOVBJUGHBJJKOW-UHFFFAOYSA-N methyl 2-amino-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1N MOVBJUGHBJJKOW-UHFFFAOYSA-N 0.000 description 1
- MTLGWFNVNBMOFC-UHFFFAOYSA-N methyl 4-[[4-(3-methylanilino)quinazolin-6-yl]amino]-4-oxobutanoate Chemical compound C12=CC(NC(=O)CCC(=O)OC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MTLGWFNVNBMOFC-UHFFFAOYSA-N 0.000 description 1
- MQQJAAAEIQKHAG-UHFFFAOYSA-N methyl 4-[[4-(3-methylanilino)quinazolin-6-yl]amino]butanoate Chemical compound C12=CC(NCCCC(=O)OC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MQQJAAAEIQKHAG-UHFFFAOYSA-N 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- ZZUYIRISBMWFMV-UHFFFAOYSA-N methyl 4-chlorobutanoate Chemical compound COC(=O)CCCCl ZZUYIRISBMWFMV-UHFFFAOYSA-N 0.000 description 1
- RUSVJCCYUALGPZ-UHFFFAOYSA-N methyl 4-oxo-1h-quinazoline-7-carboxylate Chemical compound N1C=NC(=O)C=2C1=CC(C(=O)OC)=CC=2 RUSVJCCYUALGPZ-UHFFFAOYSA-N 0.000 description 1
- UAPJKEJWOPOJJY-UHFFFAOYSA-N methyl 5-methoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1[N+]([O-])=O UAPJKEJWOPOJJY-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- VFWKRMDOKBGBLF-UHFFFAOYSA-N n,n-dimethyl-4-(3-methylanilino)quinazoline-7-carboxamide Chemical compound N=1C=NC2=CC(C(=O)N(C)C)=CC=C2C=1NC1=CC=CC(C)=C1 VFWKRMDOKBGBLF-UHFFFAOYSA-N 0.000 description 1
- XXVNQHJAVBZSFX-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-piperidin-1-ylquinazolin-4-amine;hydrochloride Chemical compound Cl.C1=C(Cl)C(Cl)=CC=C1NC1=NC=NC2=CC=C(N3CCCCC3)C=C12 XXVNQHJAVBZSFX-UHFFFAOYSA-N 0.000 description 1
- MKLLQFMZATXPIU-UHFFFAOYSA-N n-(3-methylphenyl)-6-(methylsulfanylmethyl)quinazolin-4-amine Chemical compound C12=CC(CSC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MKLLQFMZATXPIU-UHFFFAOYSA-N 0.000 description 1
- LBRNXYNVMWRILO-UHFFFAOYSA-N n-(3-methylphenyl)-6-(morpholin-4-ylmethyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CN4CCOCC4)=CC=C3N=CN=2)=C1 LBRNXYNVMWRILO-UHFFFAOYSA-N 0.000 description 1
- QUQRGGIZFWJIKA-UHFFFAOYSA-N n-(3-methylphenyl)-6-(phenylsulfanylmethyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CSC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 QUQRGGIZFWJIKA-UHFFFAOYSA-N 0.000 description 1
- YZOKGFVFCZZKBP-UHFFFAOYSA-N n-(3-methylphenyl)-6-(piperazin-1-ylmethyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CN4CCNCC4)=CC=C3N=CN=2)=C1 YZOKGFVFCZZKBP-UHFFFAOYSA-N 0.000 description 1
- USXLZROFUIENBM-UHFFFAOYSA-N n-(3-methylphenyl)-6-morpholin-4-ylquinazolin-4-amine;hydrochloride Chemical compound Cl.CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)N2CCOCC2)=C1 USXLZROFUIENBM-UHFFFAOYSA-N 0.000 description 1
- PPDJGIANUQFQRE-UHFFFAOYSA-N n-(3-methylphenyl)-7-morpholin-4-ylquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C1 PPDJGIANUQFQRE-UHFFFAOYSA-N 0.000 description 1
- DRFVJEGTGAKWBA-UHFFFAOYSA-N n-(3-methylphenyl)-[1,3]dioxolo[4,5-g]quinazolin-8-amine Chemical compound CC1=CC=CC(NC=2C3=CC=4OCOC=4C=C3N=CN=2)=C1 DRFVJEGTGAKWBA-UHFFFAOYSA-N 0.000 description 1
- JCKRUPOZHCVXTD-UHFFFAOYSA-N n-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(NC(C)=O)=C1 JCKRUPOZHCVXTD-UHFFFAOYSA-N 0.000 description 1
- BLQGAUTUIVRLHZ-UHFFFAOYSA-N n-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 BLQGAUTUIVRLHZ-UHFFFAOYSA-N 0.000 description 1
- MDBTWFDBCJAGBQ-UHFFFAOYSA-N n-[4-(3-chloroanilino)quinazolin-6-yl]-2-methoxyacetamide Chemical compound C12=CC(NC(=O)COC)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 MDBTWFDBCJAGBQ-UHFFFAOYSA-N 0.000 description 1
- OWZVFFZPZXVPLM-UHFFFAOYSA-N n-[4-(3-chloroanilino)quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 OWZVFFZPZXVPLM-UHFFFAOYSA-N 0.000 description 1
- JEZKOONZDJHDBD-UHFFFAOYSA-N n-[4-[3-(trifluoromethyl)anilino]quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JEZKOONZDJHDBD-UHFFFAOYSA-N 0.000 description 1
- VCLXUEIYTZFLMO-UHFFFAOYSA-N n-methyl-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1N(C)C1=CC=CC=C1 VCLXUEIYTZFLMO-UHFFFAOYSA-N 0.000 description 1
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FJVZDOGVDJCCCR-UHFFFAOYSA-M potassium periodate Chemical compound [K+].[O-]I(=O)(=O)=O FJVZDOGVDJCCCR-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006628 propoxycarbonylamino group Chemical group 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- VBUBADWLHFZFDK-UHFFFAOYSA-N quinazoline;hydrochloride Chemical compound Cl.N1=CN=CC2=CC=CC=C21 VBUBADWLHFZFDK-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Cosmetics (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929201095A GB9201095D0 (en) | 1992-01-20 | 1992-01-20 | Quinazoline derivatives |
GB929213572A GB9213572D0 (en) | 1992-06-26 | 1992-06-26 | Quinazoline derivatives |
GB929223735A GB9223735D0 (en) | 1992-11-12 | 1992-11-12 | Quinazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ245662A true NZ245662A (en) | 1995-09-26 |
Family
ID=27266013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ245662A NZ245662A (en) | 1992-01-20 | 1993-01-12 | Quinazoline derivatives, preparation and pharmaceutical compositions thereof |
Country Status (22)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476040B1 (en) | 1999-03-31 | 2002-11-05 | Pfizer Inc. | Processes and intermediates for preparing anti-cancer compounds |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
US6900221B1 (en) | 1999-11-11 | 2005-05-31 | Osi Pharmaceuticals, Inc. | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
Families Citing this family (701)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US7772432B2 (en) | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
PH31122A (en) * | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
AU739382B2 (en) * | 1993-12-10 | 2001-10-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
BR9506936A (pt) * | 1994-02-23 | 1997-09-09 | Pfizer | Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
ES2109796T3 (es) * | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
CA2200210A1 (en) * | 1994-09-29 | 1996-04-04 | Novartis Ag | Pyrrolo[2,3-d]pyrimidines and their use |
TW321649B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
AU778961B2 (en) * | 1995-03-30 | 2004-12-23 | Osi Pharmaceuticals, Inc. | Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives |
ATE205483T1 (de) | 1995-03-30 | 2001-09-15 | Pfizer | Chinazolinderivate |
CA2214086C (en) * | 1995-04-03 | 2008-07-29 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
US5721277A (en) * | 1995-04-21 | 1998-02-24 | Sugen, Inc. | Compounds and methods for inhibiting hyper-proliferative cell growth |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US5639757A (en) * | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6316635B1 (en) | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
EP0832073B1 (en) * | 1995-06-07 | 2002-01-16 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US7119174B2 (en) | 1995-12-18 | 2006-10-10 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
ZA9756B (en) * | 1996-01-16 | 1997-07-17 | Warner Lambert Co | Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines |
US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
EP0880508B1 (en) * | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ES2169355T3 (es) * | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
NZ333727A (en) * | 1996-08-06 | 2000-09-29 | Pfizer | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives |
RU2196137C2 (ru) * | 1996-08-08 | 2003-01-10 | Зенека Лимитед | Производные хиназолина и их применение в качестве ингибиторов фактора роста эндотелия сосудов |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
AU4342997A (en) * | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
IL129825A0 (en) * | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6818440B2 (en) | 1997-04-28 | 2004-11-16 | Sugen, Inc. | Diagnosis and treatment of alk-7 related disorders |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
US6316429B1 (en) | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
US6486185B1 (en) | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
US6228641B1 (en) | 1997-05-20 | 2001-05-08 | Sugen, Inc. | Diagnosis and treatment of PTP04 related disorders |
US7115710B2 (en) | 1997-06-11 | 2006-10-03 | Sugen, Inc. | Diagnosis and treatment of PTP related disorders |
US6342593B1 (en) | 1997-06-11 | 2002-01-29 | Sugen, Inc. | Diagnosis and treatment of ALP related disorders |
US6987113B2 (en) | 1997-06-11 | 2006-01-17 | Sugen, Inc. | Tyrosine kinase inhibitors |
US6388063B1 (en) | 1997-06-18 | 2002-05-14 | Sugen, Inc. | Diagnosis and treatment of SAD related disorders |
US6130238A (en) * | 1997-06-20 | 2000-10-10 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
US6114371A (en) * | 1997-06-20 | 2000-09-05 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
US6051593A (en) | 1997-06-20 | 2000-04-18 | Sugen, Inc. | 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors |
US6313158B1 (en) | 1997-06-20 | 2001-11-06 | Sugen, Inc. | Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors |
US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
EP1011648B2 (en) * | 1997-08-15 | 2005-07-20 | Cephalon, Inc. | Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
ATE281834T1 (de) | 1997-09-26 | 2004-11-15 | Zentaris Gmbh | Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US6531502B1 (en) | 1998-01-21 | 2003-03-11 | Sugen, Inc. | 3-Methylidenyl-2-indolinone modulators of protein kinase |
WO1999037787A2 (en) | 1998-01-21 | 1999-07-29 | Sugen, Inc. | Human orthologues of wart |
EP1367046A1 (en) | 1998-02-27 | 2003-12-03 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
JP2002522009A (ja) | 1998-04-14 | 2002-07-23 | スージェン・インコーポレーテッド | Ste−20関連蛋白質キナーゼ |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
EP1082311A1 (en) | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Quinazolines for treating brain tumor |
EP2020408B1 (en) | 1998-05-29 | 2013-06-26 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitor |
US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP2002523455A (ja) | 1998-08-31 | 2002-07-30 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された2−インドリノン誘導体 |
US6680335B2 (en) | 1998-09-28 | 2004-01-20 | Sugen, Inc. | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds |
IL142092A0 (en) | 1998-09-29 | 2002-03-10 | American Cyanamid Co | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
PT1117653E (pt) | 1998-10-01 | 2003-06-30 | Astrazeneca Ab | Derivados de quinolina e quinazolina e sua utilizacao como inibidores de doencas mediadas pela citosina |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
IL145357A0 (en) | 1999-03-17 | 2002-06-30 | Astrazeneca Ab | Amide derivatives |
US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
US7064114B2 (en) * | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
IT1312310B1 (it) * | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
JP2003520195A (ja) | 1999-05-14 | 2003-07-02 | イムクローン システムズ インコーポレイティド | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
HUP0201900A3 (en) | 1999-06-21 | 2003-02-28 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof |
WO2001004111A1 (en) | 1999-07-09 | 2001-01-18 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
DE60043349D1 (de) * | 1999-09-21 | 2009-12-31 | Astrazeneca Ab | Chinazolin-derivate und ihre verwendung als arzneimittel |
CA2384282A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
EP1229025A4 (en) * | 1999-10-01 | 2003-04-09 | Japan Energy Corp | NEW QUINAZOLINE DERIVATIVES |
GB9924092D0 (en) * | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
WO2001032632A2 (en) * | 1999-11-01 | 2001-05-10 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
US7091227B2 (en) | 2000-02-07 | 2006-08-15 | Abbott Gmbh & Co. Kg | Benzothiazole derivatives |
GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
NZ520640A (en) | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US7160889B2 (en) * | 2000-04-07 | 2007-01-09 | Astrazeneca Ab | Quinazoline compounds |
RU2276151C2 (ru) * | 2000-06-06 | 2006-05-10 | Астразенека Аб | Хиназолиновые производные для лечения опухолей |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
RU2283311C2 (ru) * | 2000-06-28 | 2006-09-10 | Астразенека Аб | Замещенные производные хиназолина и их применение в качестве ингибиторов |
WO2002011677A2 (en) * | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
PL202812B1 (pl) | 2000-08-21 | 2009-07-31 | Astrazeneca Ab | Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie |
DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
WO2002036587A2 (en) | 2000-11-01 | 2002-05-10 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
CZ200591A3 (cs) | 2001-02-19 | 2019-01-23 | Novartis Ag | 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení |
ATE340165T1 (de) * | 2001-02-26 | 2006-10-15 | Univ Mcgill | Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
EP1385983A4 (en) * | 2001-04-02 | 2005-11-16 | Merck & Co Inc | IN VIVO METHODS FOR DETERMINING THE ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORS |
MXPA03009683A (es) | 2001-04-24 | 2004-02-12 | Merck Patent Gmbh | TERAPIA EN COMBINACIoN USANDO AGENTES ANTIANGIOGENICOS Y FACTOR DE NECROSIS TUMORAL ALFA. |
AU2002311919B8 (en) * | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
WO2002092577A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
JP4477303B2 (ja) | 2001-05-16 | 2010-06-09 | ノバルティス アーゲー | N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
KR100397792B1 (ko) | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
US6642232B2 (en) | 2001-10-10 | 2003-11-04 | Sugen, Inc. | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
ATE446093T1 (de) * | 2001-12-24 | 2009-11-15 | Astrazeneca Ab | Substituierte chinazolin-derivate als aurora- kinase inhibitoren |
CN1627944A (zh) * | 2002-01-17 | 2005-06-15 | 神经能质公司 | 取代的喹唑啉-4-基胺类似物作为辣椒辣素调节剂 |
AU2003202094B2 (en) | 2002-02-01 | 2009-10-08 | Astrazeneca Ab | Quinazoline compounds |
GB0204392D0 (en) * | 2002-02-26 | 2002-04-10 | Astrazeneca Ab | Pharmaceutical compound |
US7612077B2 (en) * | 2002-02-26 | 2009-11-03 | Astrazeneca Ab | Crystalline forms of the anti-cancer compound ZD1839 |
DE60313956T2 (de) * | 2002-02-26 | 2008-05-15 | Astrazeneca Ab | Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
NZ535739A (en) * | 2002-04-16 | 2008-01-31 | Astrazeneca Ab | Combination of VTA and tyrosine kinase inhibitor receptor for the treatment of cancer |
DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
KR20120125398A (ko) | 2002-05-16 | 2012-11-14 | 노파르티스 아게 | 암에서 edg 수용체 결합제의 용도 |
AU2003251397B2 (en) | 2002-06-05 | 2009-10-01 | Genentech, Inc. | Compositions and methods for liver growth and liver protection |
GB0221245D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
MXPA05004858A (es) * | 2002-11-04 | 2005-07-22 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina de src. |
JP2006515847A (ja) * | 2002-12-13 | 2006-06-08 | ニューロジェン・コーポレーション | カプサイシン受容体調節剤としてのカルボン酸、ホスフェート又はホスホネート置換キナゾリン−4−イルアミン類縁体 |
GEP20084357B (en) | 2002-12-20 | 2008-04-29 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
KR20050122199A (ko) * | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도 |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
EP1628967B1 (en) | 2003-05-19 | 2014-04-09 | Irm Llc | Immunosuppressant compounds and compositions |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
BRPI0411250A (pt) | 2003-06-09 | 2006-08-29 | Samuel Waksal | método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular |
BRPI0411126A (pt) * | 2003-06-10 | 2006-07-18 | Hoffmann La Roche | derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
MXPA06001079A (es) * | 2003-07-29 | 2006-04-11 | Astrazeneca Ab | Derivados de piperidil quinazolina como inhibidores de cinasa de tirosina. |
GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
WO2005009969A1 (en) | 2003-07-31 | 2005-02-03 | Sanofi-Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
WO2005016875A2 (en) | 2003-08-06 | 2005-02-24 | Sugen, Inc. | Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors |
GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
RU2378268C2 (ru) | 2003-09-16 | 2010-01-10 | Астразенека Аб | Производные хиназолина в качестве ингибиторов тирозинкиназы |
CA2541100A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazenca Ab | Quinazoline derivatives |
WO2005028470A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
US8318752B2 (en) * | 2003-09-19 | 2012-11-27 | Astrazeneca Ab | 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same |
KR20060100388A (ko) * | 2003-09-25 | 2006-09-20 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
WO2005032481A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
WO2005048928A2 (en) * | 2003-11-12 | 2005-06-02 | George Mason Intellectual Property | Methods for treating viral infection |
US20050171171A1 (en) * | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as FLT-3 modulators |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
EP1759010A4 (en) * | 2004-01-07 | 2008-12-24 | Bristol Myers Squibb Co | BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS |
DE602005010824D1 (de) | 2004-02-03 | 2008-12-18 | Astrazeneca Ab | Chinazolinderivate |
BRPI0400869B8 (pt) * | 2004-03-02 | 2021-05-25 | Univ Estadual Campinas Unicamp | novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases |
EP2650286A1 (en) * | 2004-02-19 | 2013-10-16 | Rexahn Pharmaceuticals, Inc. | Quinazoline derivatives and therapeutic use thereof |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
CN102586431B (zh) | 2004-03-31 | 2015-04-22 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
PT2253614E (pt) | 2004-04-07 | 2013-01-09 | Novartis Ag | Inibidores de iap |
US8080577B2 (en) | 2004-05-06 | 2011-12-20 | Bioresponse, L.L.C. | Diindolylmethane formulations for the treatment of leiomyomas |
EP1746999B1 (en) | 2004-05-06 | 2011-11-16 | Warner-Lambert Company LLC | 4-phenylamino-quinazolin-6-yl-amides |
EP1773881A4 (en) * | 2004-05-13 | 2008-08-06 | Imclone Systems Inc | Inhibition of macrophage-stimulating protein receptor (RON) |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CA2581516C (en) | 2004-10-12 | 2013-06-11 | Astrazeneca Ab | Quinazoline derivatives |
US7947676B2 (en) | 2004-12-14 | 2011-05-24 | Astrazeneca Ab | Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents |
US7989486B2 (en) | 2004-12-30 | 2011-08-02 | Bioresponse, L.L.C. | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
US20090155247A1 (en) * | 2005-02-18 | 2009-06-18 | Ashkenazi Avi J | Methods of Using Death Receptor Agonists and EGFR Inhibitors |
PT1854789E (pt) | 2005-02-23 | 2013-10-23 | Shionogi & Co | Derivado de quinazolina possuindo actividade inibidora de tirosina-cinase |
BRPI0607432A2 (pt) | 2005-02-26 | 2009-09-01 | Astrazeneca Ab | derivado de quinazolina ou um sal farmacêuticamente aceitável do mesmo, composto, composição farmacêutica, uso de um derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo |
DE602006004976D1 (de) * | 2005-03-28 | 2009-03-12 | Bristol Myers Squibb Co | Kompetitive atp-kinasehemmer |
BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
EP1896505A2 (en) | 2005-06-15 | 2008-03-12 | Schering Corporation | Anti-igf1r antibody formulations |
ES2435727T3 (es) | 2005-06-17 | 2013-12-23 | Imclone Llc | Anticuerpo contra PDGFR-alfa para uso en el tratamiento de tumores |
CA2620195A1 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
WO2007029251A2 (en) * | 2005-09-06 | 2007-03-15 | T.K. Signal Ltd. | Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase |
ES2354457T3 (es) | 2005-09-20 | 2011-03-15 | Astrazeneca Ab | Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer. |
AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
US8404697B2 (en) | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US9006224B2 (en) | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
AU2006328194A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
CA2641310C (en) | 2006-02-03 | 2013-08-20 | Imclone Systems Incorporated | Igf-ir antagonists as adjuvants for treatment of prostate cancer |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
TWI404709B (zh) * | 2006-02-21 | 2013-08-11 | Eisai R&D Man Co Ltd | 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
EP1994024A2 (en) * | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Quinoline derivatives |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
AU2007240548A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
MX2008012728A (es) | 2006-04-05 | 2008-10-14 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento de cancer. |
AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
US20070293491A1 (en) | 2006-04-19 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Indazole compounds and methods for inhibition of cdc7 |
BRPI0711385A2 (pt) | 2006-05-09 | 2011-11-08 | Novartis Ag | combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso |
BRPI0711358A2 (pt) | 2006-05-09 | 2011-09-27 | Pfizer Prod Inc | derivados do ácido cicloalquilamino e suas composições farmacêuticas |
CA2655997A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
CN101100466B (zh) | 2006-07-05 | 2013-12-25 | 天津和美生物技术有限公司 | 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用 |
EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
US8604044B2 (en) * | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
CA2662587C (en) * | 2006-09-11 | 2013-08-06 | Curis, Inc. | Quinazoline based egfr inhibitors |
CA2662236A1 (en) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
BRPI0717586A2 (pt) | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
EP2077819A4 (en) * | 2006-09-28 | 2011-05-25 | Follica Inc | PROCESSES, KITS AND COMPOSITIONS FOR PRODUCING NEW HAIRFOLLICLES AND GROWING HAIR |
RU2009115954A (ru) | 2006-09-29 | 2010-11-10 | Новартис АГ (CH) | Пиразолопиримидины в качестве ингибиторов липидной киназы р13к |
JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
US8586621B2 (en) | 2006-10-27 | 2013-11-19 | Michael A. Zeligs | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CN101711284A (zh) | 2007-01-25 | 2010-05-19 | 达娜-法勃肿瘤研究所 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
CN101245050A (zh) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
CA2677651A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
JP5618549B2 (ja) | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤 |
BRPI0809715A2 (pt) | 2007-04-16 | 2019-11-05 | Hutchison Medipharma Entpr Ltd | "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" |
BRPI0810411B8 (pt) | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
JP2010527951A (ja) * | 2007-05-24 | 2010-08-19 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体 |
CA2696360C (en) * | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
WO2009035718A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
JP2011500723A (ja) * | 2007-10-19 | 2011-01-06 | ファルマ・マール・ソシエダード・アノニマ | 改善された抗腫瘍治療 |
CN101918579A (zh) * | 2007-10-22 | 2010-12-15 | 先灵公司 | 完全人抗-vegf抗体和使用方法 |
UA101168C2 (ru) | 2007-10-29 | 2013-03-11 | Натко Фарма Лимитед | 4-(тетразол-5-ил)хиназолиновые производные как противораковые средства |
SG185942A1 (en) | 2007-11-02 | 2012-12-28 | Agency Science Tech & Res | Methods and compounds for preventing and treating a tumour |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
US20110053991A1 (en) * | 2007-11-19 | 2011-03-03 | Gore Lia | Treatment of Histone Deacetylase Mediated Disorders |
WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
UY31478A1 (es) * | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
EP2072502A1 (de) * | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
EA201000947A1 (ru) | 2007-12-20 | 2011-02-28 | Новартис Аг | Производные тиазола, применимые в качестве ингибиторов киназы pi3 |
HRP20161522T1 (hr) | 2008-01-18 | 2017-02-10 | Natco Pharma Limited | Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom |
AU2009209541A1 (en) * | 2008-01-30 | 2009-08-06 | Pharma Mar, S.A. | Improved antitumoral treatments |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
JP5336516B2 (ja) | 2008-02-07 | 2013-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法 |
DE102008009609A1 (de) | 2008-02-18 | 2009-08-20 | Freie Universität Berlin | Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung |
KR20100131446A (ko) * | 2008-03-05 | 2010-12-15 | 노파르티스 아게 | Egfr 의존성 질환 또는 egfr 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |
KR20100126479A (ko) * | 2008-03-07 | 2010-12-01 | 파르마 마르 에스.에이. | 개선된 항종양 치료법들 |
ES2524259T3 (es) | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
EP2260020B1 (en) | 2008-03-26 | 2014-07-23 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
WO2009126691A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
TW201008933A (en) * | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
KR20160129915A (ko) | 2008-12-18 | 2016-11-09 | 노파르티스 아게 | 1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염 |
CA2746764A1 (en) | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
CN102256941A (zh) | 2008-12-18 | 2011-11-23 | 诺瓦提斯公司 | 新的盐 |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
EP2391366B1 (en) | 2009-01-29 | 2012-11-28 | Novartis AG | Substituted benzimidazoles for the treatment of astrocytomas |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010107968A1 (en) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
UA106070C2 (uk) | 2009-03-20 | 2014-07-25 | Дженентек, Інк. | Антитіло, що специфічно зв'язується з egfr і her3 |
CA2757679A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
CA2757622A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
HRP20140593T1 (hr) | 2009-06-26 | 2014-08-01 | Novartis Ag | Derivati 1,3-disupstituiranih imidazolidin-2-ona kao cyp 17-inhibitori |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
HRP20191005T1 (hr) | 2009-07-06 | 2019-08-23 | Boehringer Ingelheim International Gmbh | Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak |
US9050341B2 (en) | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
IN2012DN01961A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
CA2771936A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
NZ598516A (en) | 2009-09-03 | 2013-02-22 | Bristol Myers Squibb Co | Quinazolines as potassium ion channel inhibitors |
MX2012002997A (es) | 2009-09-10 | 2012-08-01 | Novartis Ag | Derivados de eter de los heteroarilos biciclicos. |
US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
BR112012011328A2 (pt) | 2009-10-23 | 2016-11-22 | Lilly Co Eli | inibidores de akt |
EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
CN102596951B (zh) | 2009-11-04 | 2015-04-15 | 诺华股份有限公司 | 用作mek抑制剂的杂环磺酰胺衍生物 |
JP2013510871A (ja) | 2009-11-12 | 2013-03-28 | ジェネンテック, インコーポレイテッド | 樹状突起棘の密度を促す方法 |
CA2780875A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
MX2012005987A (es) | 2009-11-23 | 2012-06-25 | Cerulean Pharma Inc | Polimeros a base de ciclodextrina para administracion terapeutica. |
JP2013512215A (ja) | 2009-11-25 | 2013-04-11 | ノバルティス アーゲー | 二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体 |
KR20120102750A (ko) | 2009-12-08 | 2012-09-18 | 노파르티스 아게 | 헤테로시클릭 술폰아미드 유도체 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
AR079984A1 (es) | 2010-01-12 | 2012-03-07 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1 |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
WO2011097233A1 (en) * | 2010-02-03 | 2011-08-11 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
MX2012008958A (es) | 2010-02-18 | 2012-08-23 | Genentech Inc | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. |
KR20130017086A (ko) | 2010-03-16 | 2013-02-19 | 메르크 파텐트 게엠베하 | 모르폴리닐퀴나졸린 |
US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
TWI406853B (zh) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Egfr與vegfr-2雙重抑制劑及其用途與製法 |
KR20130058672A (ko) | 2010-04-16 | 2013-06-04 | 제넨테크, 인크. | PI3K/AKT 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 FOXO3a |
EP2582681A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
US20130090342A1 (en) | 2010-06-17 | 2013-04-11 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
SG10201408229WA (en) | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
TW201217387A (en) | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
WO2012066061A1 (en) | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
CN103270026A (zh) | 2010-12-21 | 2013-08-28 | 诺瓦提斯公司 | 作为vps34抑制剂的联-杂芳基化合物 |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
WO2012104776A1 (en) | 2011-01-31 | 2012-08-09 | Novartis Ag | Novel heterocyclic derivatives |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
AU2012225693A1 (en) | 2011-03-04 | 2013-09-19 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
WO2012120469A1 (en) | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
US9321759B2 (en) | 2011-03-17 | 2016-04-26 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
WO2012125904A1 (en) | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of egfr |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012155339A1 (zh) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
JP2014517004A (ja) | 2011-06-09 | 2014-07-17 | ノバルティス アーゲー | 複素環スルホンアミド誘導体 |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
EA201490164A1 (ru) | 2011-06-27 | 2014-04-30 | Новартис Аг | Твердые формы и соли производных тетрагидропиридопиримидина |
WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
JP5855253B2 (ja) | 2011-08-12 | 2016-02-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インダゾール化合物、組成物及び使用方法 |
RU2014109093A (ru) | 2011-08-17 | 2015-09-27 | Дженентек, Инк. | Антитела против нейрегулина и их применение |
EP2758043A4 (en) | 2011-08-17 | 2016-02-24 | Dennis M Brown | COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
CN103827115A (zh) | 2011-09-20 | 2014-05-28 | 弗·哈夫曼-拉罗切有限公司 | 咪唑并吡啶化合物、组合物和使用方法 |
WO2013042006A1 (en) | 2011-09-22 | 2013-03-28 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
EP2761025A1 (en) | 2011-09-30 | 2014-08-06 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
WO2013056069A1 (en) | 2011-10-13 | 2013-04-18 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
CN104039790B (zh) | 2011-10-28 | 2016-04-13 | 诺华股份有限公司 | 嘌呤衍生物及它们在治疗疾病中的应用 |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
RU2019103083A (ru) | 2011-11-30 | 2019-03-22 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
EP2796451B1 (en) | 2011-12-20 | 2018-08-01 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
MA37142B1 (fr) | 2011-12-22 | 2019-07-31 | Novartis Ag | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine |
MX2014007729A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
EP2794589A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
MX2014007730A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
BR112014015308A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
JP2015503519A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Bcl2と結合相手の相互作用を阻害するための化合物 |
JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
WO2013143057A1 (zh) | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
RU2660354C2 (ru) | 2012-04-03 | 2018-07-05 | Новартис Аг | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CN103373966A (zh) * | 2012-04-17 | 2013-10-30 | 南京大学 | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 |
US10213432B2 (en) | 2012-05-16 | 2019-02-26 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
JP6427097B2 (ja) | 2012-06-15 | 2018-11-21 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 癌を処置するための組成物および該組成物を製造するための方法 |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
EP2879675B1 (en) | 2012-08-06 | 2019-11-13 | Duke University | Compounds and methods for targeting hsp90 |
EP2890706A1 (en) | 2012-08-31 | 2015-07-08 | Westfälische Wilhelms-Universität Münster | Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
CN110787285B (zh) | 2012-11-05 | 2025-06-13 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法 |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
US10030015B2 (en) | 2013-02-01 | 2018-07-24 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗EGFRvIIIキメラ抗原受容体を用いたがんの処置 |
BR112015019624A2 (pt) | 2013-02-21 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | quinazolinas como inibidores de quinase |
KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
PT2964638T (pt) | 2013-03-06 | 2017-11-14 | Astrazeneca Ab | Inibidores quinazolina de formas mutantes de ativação do recetor do fator de crescimento epidérmico |
HK1213180A1 (zh) | 2013-03-06 | 2016-06-30 | 豪夫迈‧罗氏有限公司 | 治疗和预防癌症药物抗性的方法 |
US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
HK1220916A1 (zh) | 2013-03-14 | 2017-05-19 | 基因泰克公司 | 治療癌症和預防癌症藥物抗性的方法 |
CA2903480A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
JP2016520528A (ja) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | 癌の治療及び抗癌剤耐性の防止方法 |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
WO2014147631A1 (en) | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
JP6268276B2 (ja) | 2013-04-04 | 2018-01-24 | ヤンセン ファーマシューティカ エヌ.ベー. | PERK阻害剤としての新規なN(2,3−ジヒドロ−1H−ピロロ[2,3−b]ピリジン−5−イル)−4−キナゾリンアミン誘導体およびN−(2,3−ジヒドロ−1H−インドール−5−イル)−4−キナゾリンアミン誘導体 |
CN103275019B (zh) * | 2013-04-26 | 2016-05-18 | 浙江工业大学 | 4-[3-氯-4-取代苯胺基]-6-取代甲氧基甲酰氨基喹唑啉类化合物及制备和应用 |
US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
CN103382182B (zh) * | 2013-05-17 | 2016-08-10 | 河北医科大学 | 苯基脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途 |
CN103304491A (zh) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | 一种吉非替尼的制备方法 |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
CA2922925A1 (en) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
AU2014321419B2 (en) | 2013-09-22 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CN103483276B (zh) * | 2013-09-22 | 2018-04-17 | 南京恒道医药科技有限公司 | 一种凡德他尼杂质的制备方法 |
WO2015049325A1 (en) | 2013-10-03 | 2015-04-09 | F. Hoffmann-La Roche Ag | Therapeutic inhibitors of cdk8 and uses thereof |
TWI658052B (zh) | 2013-10-18 | 2019-05-01 | 美商建南德克公司 | 抗-rspo抗體及使用方法 |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
AU2014358773A1 (en) | 2013-12-06 | 2016-06-02 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
KR20240017102A (ko) | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
US10000469B2 (en) | 2014-03-25 | 2018-06-19 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
WO2015144804A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations |
WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
US9394281B2 (en) | 2014-03-28 | 2016-07-19 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
BR112016022345A2 (pt) | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
PT3126394T (pt) | 2014-03-31 | 2019-12-19 | Hoffmann La Roche | Anticorpos anti-ox40 e métodos de utilização |
KR20160132496A (ko) | 2014-04-03 | 2016-11-18 | 인빅터스 온콜로지 피비티. 엘티디. | 초분자 조합 치료제 |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
US20170050958A1 (en) | 2014-04-30 | 2017-02-23 | Pfizer Inc. | Cycloalkyl-Linked Diheterocycle Derivatives |
US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
WO2016057924A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
MX2017005751A (es) | 2014-11-03 | 2018-04-10 | Genentech Inc | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. |
AU2015343337A1 (en) | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Assays for detecting T cell immune subsets and methods of use thereof |
EP3215536A1 (en) | 2014-11-06 | 2017-09-13 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
EP3221360A1 (en) | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CN107531690B (zh) | 2014-11-27 | 2020-11-06 | 基因泰克公司 | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 |
KR20170094165A (ko) | 2014-12-23 | 2017-08-17 | 제넨테크, 인크. | 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법 |
MY188938A (en) | 2014-12-24 | 2022-01-13 | Genentech Inc | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
JP2018503373A (ja) | 2014-12-30 | 2018-02-08 | ジェネンテック, インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
WO2016112284A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
EP3242874B1 (en) | 2015-01-09 | 2018-10-31 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
EP3242875B1 (en) | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
WO2016123391A1 (en) | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
CN107438593B (zh) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | 治疗化合物及其用途 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CN107709364A (zh) | 2015-04-07 | 2018-02-16 | 豪夫迈·罗氏有限公司 | 具有激动剂活性的抗原结合复合体及使用方法 |
ES2835866T5 (es) | 2015-05-12 | 2024-12-02 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
MX392671B (es) | 2015-05-29 | 2025-03-24 | Genentech Inc | Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer |
CA2985483A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
CA2988420A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
IL256080B2 (en) | 2015-06-17 | 2025-06-01 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
CN107922609B (zh) | 2015-07-01 | 2020-04-24 | 加州理工学院 | 基于阳离子粘酸聚合物的递送系统 |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
CN105001167B (zh) * | 2015-07-16 | 2018-01-05 | 西安交通大学 | 1‑取代苯基‑3‑(4‑取代苯基氨基‑6‑喹唑啉基)脲类化合物及制备方法和用途 |
EP3341376B1 (en) | 2015-08-26 | 2020-12-23 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Condensed tricyclic compounds as protein kinase inhibitors |
US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
SI3353210T1 (sl) | 2015-09-25 | 2025-03-31 | F. Hoffmann-La Roche Ag | Protitelesa proti TIGIT in postopki uporabe |
CA3000988A1 (en) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
EP3913068B1 (en) | 2015-10-12 | 2023-08-02 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
JP2018532750A (ja) | 2015-11-02 | 2018-11-08 | ノバルティス アーゲー | ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン |
PL3389662T3 (pl) | 2015-12-16 | 2022-04-04 | Genentech, Inc. | Sposób wytwarzania trójpierścieniowych związków inhibitorów pi3k oraz sposoby ich zastosowania do leczenia raka |
US10259805B2 (en) | 2015-12-30 | 2019-04-16 | Synthon B.V. | Process for making crystalline form a of gefitinib |
BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
WO2017122205A1 (en) | 2016-01-13 | 2017-07-20 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
JP7503887B2 (ja) | 2016-04-15 | 2024-06-21 | ジェネンテック, インコーポレイテッド | がんを監視及び治療するための方法 |
MX2018012493A (es) | 2016-04-15 | 2019-06-06 | Genentech Inc | Métodos para controlar y tratar el cáncer. |
JP2019518426A (ja) | 2016-04-15 | 2019-07-04 | ジェネンテック, インコーポレイテッド | がんの診断及び治療方法 |
WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
CN109476641B (zh) | 2016-05-24 | 2022-07-05 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
MA45146A (fr) | 2016-05-24 | 2021-03-24 | Constellation Pharmaceuticals Inc | Dérivés de pyrazolopyridine pour le traitement du cancer |
CN109312407A (zh) | 2016-06-08 | 2019-02-05 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
JP2019530434A (ja) | 2016-08-05 | 2019-10-24 | ジェネンテック, インコーポレイテッド | アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法 |
EP3497129A1 (en) | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
WO2018039205A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
ES2912269T3 (es) | 2016-09-27 | 2022-05-25 | Cero Therapeutics Inc | Moléculas de receptor de engullimiento quimérico |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
EP3523451A1 (en) | 2016-10-06 | 2019-08-14 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
JP2019535250A (ja) | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | 抗mic抗体及び使用方法 |
ES2894255T3 (es) | 2016-12-22 | 2022-02-14 | Amgen Inc | Derivados de benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibidores de KRAS G12C para tratar el cáncer de pulmón, pancreático o colorrectal |
JP7053665B2 (ja) * | 2016-12-30 | 2022-04-12 | 南京明徳新薬研発有限公司 | Egfr阻害としてのキナゾリン系化合物 |
EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
CN110505883A (zh) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
UA125730C2 (uk) | 2017-06-22 | 2022-05-25 | Курадев Фарма Лімітед | Низькомолекулярні модулятори sting людини |
KR20200093518A (ko) | 2017-07-21 | 2020-08-05 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
WO2019033043A2 (en) | 2017-08-11 | 2019-02-14 | Genentech, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
US11859252B2 (en) | 2017-09-08 | 2024-01-02 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
CN111386284B (zh) | 2017-09-26 | 2024-08-30 | 森罗治疗公司 | 嵌合吞噬受体分子和使用方法 |
WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
AU2018353984A1 (en) | 2017-10-24 | 2020-05-07 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
EP3710001B1 (en) | 2017-10-27 | 2025-06-18 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting avil expression |
WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
US11708335B2 (en) | 2017-12-18 | 2023-07-25 | Sterngreene, Inc. | Pyrimidine compounds useful as tyrosine kinase inhibitors |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
US12174193B2 (en) | 2018-01-15 | 2024-12-24 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
CA3083040A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
KR20200135313A (ko) | 2018-02-26 | 2020-12-02 | 제넨테크, 인크. | 항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약 |
US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
MX2020010241A (es) | 2018-03-28 | 2020-10-16 | Cero Therapeutics Inc | Composiciones de inmunoterapia celular y usos de las mismas. |
CN112218886A (zh) | 2018-03-28 | 2021-01-12 | 森罗治疗公司 | 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途 |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
US20210363590A1 (en) | 2018-05-21 | 2021-11-25 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
EP4268898A3 (en) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
US20200030443A1 (en) | 2018-06-23 | 2020-01-30 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
AU2019305637A1 (en) | 2018-07-18 | 2021-03-11 | Genentech, Inc. | Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent |
WO2020023628A1 (en) | 2018-07-24 | 2020-01-30 | Hygia Pharmaceuticals, Llc | Compounds, derivatives, and analogs for cancer |
TW202024023A (zh) | 2018-09-03 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
CN113195470B (zh) * | 2018-09-13 | 2024-12-03 | 南加州大学 | 作为治疗剂的新型单磷酸鸟苷合成酶抑制剂 |
JP2022501332A (ja) | 2018-09-19 | 2022-01-06 | ジェネンテック, インコーポレイテッド | 膀胱がんの治療方法および診断方法 |
AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
CA3116424A1 (en) | 2018-10-17 | 2020-04-23 | The University Of Queensland | Epigenetic biomarker and uses therefor |
CN113196061A (zh) | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 肉瘤样肾癌的诊断和治疗方法 |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
MX2021007104A (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a. |
JP2022519649A (ja) | 2019-02-08 | 2022-03-24 | ジェネンテック, インコーポレイテッド | がんの診断および治療方法 |
CN113677994B (zh) | 2019-02-27 | 2025-09-09 | 外延轴治疗股份有限公司 | 用于评估t细胞功能和预测对疗法的应答的方法和药剂 |
BR112021016923A2 (pt) | 2019-02-27 | 2021-11-03 | Genentech Inc | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
CN109796415B (zh) * | 2019-03-29 | 2020-10-30 | 武汉德诺美生物医药股份有限公司 | Egfr抑制剂及其应用 |
WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
MX2021013222A (es) | 2019-05-03 | 2022-01-06 | Genentech Inc | Metodos para tratar el cancer con un anticuerpo anti-pd-l1. |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
MX2022001296A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
MX2022001181A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
JP2022542392A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
AR119887A1 (es) | 2019-09-04 | 2022-01-19 | Genentech Inc | Agentes de unión a cd8 y sus usos |
CR20220127A (es) | 2019-09-27 | 2022-05-27 | Genentech Inc | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 |
WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
EP4051674A1 (en) | 2019-10-29 | 2022-09-07 | F. Hoffmann-La Roche AG | Bifunctional compounds for the treatment of cancer |
AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
CN115873020B (zh) | 2019-11-04 | 2025-06-13 | 锐新医药公司 | Ras抑制剂 |
TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
US20220389103A1 (en) | 2019-11-06 | 2022-12-08 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
CR20220200A (es) | 2019-11-08 | 2022-07-28 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos |
EP4058435A1 (en) | 2019-11-13 | 2022-09-21 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
AU2020381492A1 (en) | 2019-11-14 | 2022-05-26 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
CR20230209A (es) | 2019-12-13 | 2023-06-14 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso |
CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
BR112022010086A2 (pt) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | Dosagem do inibidor de shp2 e métodos de tratamento de câncer |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
EP4096646A1 (en) | 2020-01-27 | 2022-12-07 | Genentech, Inc. | Methods for treatment of cancer with an anti-tigit antagonist antibody |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CN115768890A (zh) | 2020-04-15 | 2023-03-07 | 加州理工学院 | 通过分子和物理启动对t细胞免疫疗法的热控制 |
JP2023523450A (ja) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
CN111499583B (zh) * | 2020-05-22 | 2022-02-15 | 沈阳工业大学 | 喹唑啉衍生物及其作为抗肿瘤药物的应用 |
IL299039A (en) | 2020-06-16 | 2023-02-01 | Genentech Inc | Methods and preparations for the treatment of triple-negative breast cancer |
CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
EP4189121A1 (en) | 2020-08-03 | 2023-06-07 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
US20230285576A1 (en) | 2020-08-05 | 2023-09-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
US11999964B2 (en) | 2020-08-28 | 2024-06-04 | California Institute Of Technology | Synthetic mammalian signaling circuits for robust cell population control |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
IL301547A (en) | 2020-10-05 | 2023-05-01 | Genentech Inc | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
MX2023009379A (es) | 2021-02-12 | 2023-10-10 | Hoffmann La Roche | Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer. |
AU2022227021A1 (en) | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
JP2024517847A (ja) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
KR20240026948A (ko) | 2021-05-25 | 2024-02-29 | 에라스카, 아이엔씨. | 황 함유 헤테로방향족 트리사이클릭 kras 억제제 |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
KR20240119868A (ko) | 2021-07-28 | 2024-08-06 | 세로 테라퓨틱스, 인코포레이티드 | 키메라 tim4 수용체 및 이의 용도 |
WO2023018699A1 (en) | 2021-08-10 | 2023-02-16 | Erasca, Inc. | Selective kras inhibitors |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
EP4436969A2 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Bicyclic therapeutic compounds and methods of use in the treatment of cancer |
JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック, インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
CN119212994A (zh) | 2021-12-17 | 2024-12-27 | 建新公司 | 作为shp2抑制剂的吡唑并吡嗪化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
IL315770A (en) | 2022-04-01 | 2024-11-01 | Genentech Inc | Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies |
JP2025517650A (ja) | 2022-05-11 | 2025-06-10 | ジェネンテック, インコーポレイテッド | 抗FcRH5/抗CD3二重特異性抗体による処置のための投与 |
CN119856056A (zh) | 2022-06-07 | 2025-04-18 | 基因泰克公司 | 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法 |
CN119998298A (zh) | 2022-06-10 | 2025-05-13 | 锐新医药公司 | 大环ras抑制剂 |
TW202417042A (zh) | 2022-07-13 | 2024-05-01 | 美商建南德克公司 | 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥 |
JP2025523845A (ja) | 2022-07-19 | 2025-07-25 | ジェネンテック, インコーポレイテッド | 抗fcrh5/抗cd3二重特異性抗体による処置のための投薬 |
JP2025525845A (ja) | 2022-08-02 | 2025-08-07 | 国立大学法人北海道大学 | オルガネラ複合体による細胞療法を改善する方法 |
CN119677733A (zh) | 2022-08-11 | 2025-03-21 | 豪夫迈·罗氏有限公司 | 双环四氢硫氮杂䓬衍生物 |
TW202417439A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫噻吖呯衍生物 |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
CN119677732A (zh) | 2022-08-11 | 2025-03-21 | 豪夫迈·罗氏有限公司 | 双环四氢氮杂䓬衍生物 |
CN120359029A (zh) | 2022-10-14 | 2025-07-22 | 黑钻治疗公司 | 使用异喹啉或6-氮杂-喹啉衍生物治疗癌症的方法 |
WO2024085242A2 (en) | 2022-10-21 | 2024-04-25 | Kawasaki Institute Of Industrial Promotion | Non-fouling or super stealth vesicle |
TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
TW202434206A (zh) | 2023-02-17 | 2024-09-01 | 美商伊瑞斯卡公司 | Kras抑制劑 |
TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ras gtp水解之組合物及其用途 |
WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
TW202448949A (zh) | 2023-05-05 | 2024-12-16 | 美商建南德克公司 | 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥 |
TW202504641A (zh) | 2023-06-08 | 2025-02-01 | 美商建南德克公司 | 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵 |
WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US398749A (en) * | 1889-02-26 | Harvey d | ||
US3985742A (en) * | 1971-12-01 | 1976-10-12 | Merck & Co., Inc. | Process for preparing 3-hydroxymethyl cephalosporins |
US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
JPS5620577A (en) * | 1979-07-27 | 1981-02-26 | Sankyo Co Ltd | 4- n-alkylanilino quinazoline derivative and its preparation |
US4510307A (en) * | 1980-08-20 | 1985-04-09 | Asahi Kasei Kogyo Kabushiki Kaisha | 6-Quinazolinesulfonyl derivatives and process for preparation thereof |
JPS57143266A (en) * | 1981-02-27 | 1982-09-04 | Shin Kobe Electric Mach Co Ltd | Plate for lead acid battery |
JPS57143296A (en) * | 1981-02-28 | 1982-09-04 | Matsushita Electric Works Ltd | Switching unit |
JPS5913765A (ja) * | 1982-07-15 | 1984-01-24 | Kyorin Pharmaceut Co Ltd | 2−(4−キナゾリル)アミノ安息香酸誘導体 |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
GB8424979D0 (en) * | 1984-10-03 | 1984-11-07 | Wyeth John & Brother Ltd | Benzenesulphonamide derivatives |
HU207287B (en) * | 1989-01-17 | 1993-03-29 | Biosignal Kutato Fejlesztoe Kf | Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component |
DE69202243T2 (de) * | 1991-02-20 | 1995-08-31 | Pfizer | 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen. |
SG64322A1 (en) * | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
-
1993
- 1993-01-04 GB GB939300059A patent/GB9300059D0/en active Pending
- 1993-01-04 AU AU31010/93A patent/AU661533B2/en not_active Expired
- 1993-01-08 CA CA002086968A patent/CA2086968C/en not_active Expired - Lifetime
- 1993-01-12 NZ NZ245662A patent/NZ245662A/en not_active IP Right Cessation
- 1993-01-15 EP EP93300270A patent/EP0566226B1/en not_active Expired - Lifetime
- 1993-01-15 DE DE69300754T patent/DE69300754T2/de not_active Expired - Lifetime
- 1993-01-15 AT AT93300270T patent/ATE130000T1/de active
- 1993-01-15 HU HU9300094A patent/HU221622B1/hu unknown
- 1993-01-15 DK DK93300270.1T patent/DK0566226T3/da active
- 1993-01-15 ES ES93300270T patent/ES2078798T3/es not_active Expired - Lifetime
- 1993-01-18 CZ CZ9343A patent/CZ282038B6/cs not_active IP Right Cessation
- 1993-01-18 TW TW082100292A patent/TW283146B/zh not_active IP Right Cessation
- 1993-01-19 SK SK16-93A patent/SK281551B6/sk not_active IP Right Cessation
- 1993-01-19 NO NO930178A patent/NO301541B1/no not_active IP Right Cessation
- 1993-01-19 RU RU93004423/04A patent/RU2127263C1/ru active
- 1993-01-19 FI FI930208A patent/FI111631B/fi not_active IP Right Cessation
- 1993-01-20 KR KR1019930000645A patent/KR100229294B1/ko not_active Expired - Lifetime
- 1993-01-21 IL IL10447993A patent/IL104479A/en not_active IP Right Cessation
- 1993-04-22 UA UA93002840A patent/UA34426C2/uk unknown
-
1994
- 1994-08-02 US US08/284,293 patent/US5457105A/en not_active Expired - Lifetime
-
1995
- 1995-06-12 HU HU95P/P00185P patent/HU211311A9/hu unknown
- 1995-06-15 US US08/490,666 patent/US5616582A/en not_active Expired - Lifetime
- 1995-11-21 GR GR950403262T patent/GR3018143T3/el unknown
-
1997
- 1997-03-27 HK HK36497A patent/HK36497A/en not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
US7521456B2 (en) | 1998-04-29 | 2009-04-21 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
US6476040B1 (en) | 1999-03-31 | 2002-11-05 | Pfizer Inc. | Processes and intermediates for preparing anti-cancer compounds |
US6900221B1 (en) | 1999-11-11 | 2005-05-31 | Osi Pharmaceuticals, Inc. | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2086968C (en) | Quinazoline derivatives | |
US5475001A (en) | Quinazoline derivatives | |
US6015814A (en) | Quinazoline derivative | |
EP0602851B1 (en) | Quinazoline derivatives | |
US5770599A (en) | Quinazoline derivatives | |
US5942514A (en) | Quinazoline derivatives | |
US5952333A (en) | Quinazoline derivative | |
US5880130A (en) | 4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors | |
US5932574A (en) | Quinazoline derivatives | |
JP2994165B2 (ja) | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 | |
NZ243082A (en) | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof | |
HK1005371B (en) | Quinazoline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
EXPY | Patent expired |